News
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
Danish leader will face a challenging landscape among competitors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback